Avadel Pharmaceuticals PR Confirms Favorable Ruling On Motion To Delist REMS Patent From FDA’s Orange Book
Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that the United States District Court for the District of Delaware (the